Showing results (31-40 of 39) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Journal of Medicinal Chemistry|November 28, 2006
Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonistDavid Chatenet, Christophe Dubessy, Cédric Boularan, et al.Bioorganic & Medicinal Chemistry Letters|July 13, 2002
N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activitiesNicolas Inguimbert, Hervé Poras, Franck Teffo, et al.Journal of Cell Science|February 28, 2002
Human p63RhoGEF, a novel RhoA-specific guanine nucleotide exchange factor, is localized in cardiac sarcomereMichel Souchet, Elodie Portales-Casamar, David Mazurais, et al.Journal of Enzyme Inhibition and Medicinal Chemistry|August 29, 2003
Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contractionPatricia Labarrère, David Chatenet, Jérôme Leprince, et al.Journal of Neurochemistry|August 20, 2008
Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junctionChristophe Dubessy, Dorthe Cartier, Benoît Lectez, et al.Peptides|October 13, 2007
Structure-activity relationships of urotensin II and URPJérôme Leprince, David Chatenet, Christophe Dubessy, et al.European Journal of Emergency Medicine : Official Journal of the European Society for Emergency Medicine|May 29, 2004
Beneficial effects of direct call to emergency medical services in acute myocardial infarctionBruno Cabrita, Florence Bouyer-Dalloz, Isabelle L'Huillier, et al.Peptides|October 13, 2004
Structure-activity relationships and structural conformation of a novel urotensin II-related peptideDavid Chatenet, Christophe Dubessy, Jérôme Leprince, et al.IEEE Journal of Biomedical and Health Informatics|August 11, 2022
Toward A Regulatory Pathway for the Use of in Silico Trials in the CE Marking of Medical DevicesFrancesco Pappalardo, John Wilkinson, Francois Busquet, et al.Pageof 4